Abstract: The invention relates to a human recombinant monoclonal antibody or antibody fragment that binds the receptor binding domain (RBD) of the S1 subunit (S1) of a Spike glycoprotein of SARS-CoV-2, wherein the heavy and light chain variable amino acid sequences of the antibody (VH and VL) were isolated from convalescent COVID-19 patients. In further aspects, the invention relates to a nucleic acid molecule encoding an antibody or antibody fragment of the invention, a host cell comprising the nucleic acid molecule, and a pharmaceutical composition comprising an antibody or antibody fragment of the invention. The invention further relates to corresponding medical uses and therapeutic methods of administering an antibody or antibody fragment of the invention in the treatment and/or prevention of a medical condition associated with a SARS Coronavirus, in addition to diagnostic uses and methods.

Abstract: The invention relates to a chimeric autoantibody receptor (CAAR) and nucleic acid molecules encoding said CAAR, wherein the CAAR comprises an extracellular domain comprising an autoantigen of a nicotinic acetylcholine receptor (nAChR) or fragment thereof. The invention relates further to a vector comprising a nucleic acid molecule encoding the CAAR, to a CAAR polypeptide, to a genetically modified cell expressing the CAAR or comprising a nucleic acid molecule or a vector encoding the CAAR. The invention relates further to genetically modified cells expressing the CAAR for use in the treatment of a neuromuscular disorder associated with autoantibodies that bind a nicotinic acetylcholine receptor (nAChR), preferably for the treatment of myasthenia gravis (MG).

Abstract: A soluble N-methyl-D-aspartate receptor (NMDAR) protein construct includes one or more NMDAR autoantibody epitopes. The construct includes an extracellular domain (ECD) of the NMDAR subunit GluN1 or a fragment of the subunit and an ECD of at least one of the NMDAR subunits GluN2A, GluN2B, GluN2C or GluN2D, or fragment of these subunits. An in vitro method for the detection of NMDAR autoantibodies in a sample includes providing a sample suspected of including NMDAR autoantibodies, providing the NMDAR protein construct as a capture molecule, contacting the sample with the NMDAR protein construct, thereby binding NMDAR autoantibodies from the sample to the NMDAR protein construct, and determining the presence and optionally the amount of bound NMDAR autoantibodies. The method is applied for the diagnosis, prognosis, disease monitoring, patient stratification and/or therapy monitoring of a medical condition associated with autoantibodies against the NMDAR, preferably anti-NMDAR encephalitis.

Abstract: A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system.